Ci Investments Trimmed Its Amgen (AMGN) Position; Allstate (ALL) Sentiment Is 0.96

May 20, 2018 - By Hazel Jackson

The Allstate Corporation (NYSE:ALL) Logo

Ci Investments Inc decreased Amgen Inc (AMGN) stake by 70.17% reported in 2017Q4 SEC filing. Ci Investments Inc sold 89,141 shares as Amgen Inc (AMGN)’s stock declined 2.99%. The Ci Investments Inc holds 37,898 shares with $6.59M value, down from 127,039 last quarter. Amgen Inc now has $117.42B valuation. The stock increased 0.94% or $1.65 during the last trading session, reaching $176.3. About 2.99M shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 3.78% since May 20, 2017 and is uptrending. It has underperformed by 7.77% the S&P500.

Allstate Corp (ALL) investors sentiment increased to 0.96 in 2017 Q4. It’s up 0.05, from 0.91 in 2017Q3. The ratio is positive, as 337 investment professionals opened new and increased equity positions, while 351 reduced and sold their stakes in Allstate Corp. The investment professionals in our database now hold: 266.22 million shares, up from 263.23 million shares in 2017Q3. Also, the number of investment professionals holding Allstate Corp in top ten equity positions increased from 15 to 17 for an increase of 2. Sold All: 43 Reduced: 308 Increased: 236 New Position: 101.

Analysts await The Allstate Corporation (NYSE:ALL) to report earnings on August, 7. They expect $1.60 EPS, up 15.94% or $0.22 from last year’s $1.38 per share. ALL’s profit will be $562.38M for 14.83 P/E if the $1.60 EPS becomes a reality. After $2.96 actual EPS reported by The Allstate Corporation for the previous quarter, Wall Street now forecasts -45.95% negative EPS growth.

Taylor Asset Management Inc holds 11.05% of its portfolio in The Allstate Corporation for 300,800 shares. Rr Partners Lp owns 1.42 million shares or 9.89% of their US portfolio. Moreover, Bruce & Co. Inc. has 7.57% invested in the company for 333,800 shares. The California-based Wilsey Asset Management Inc has invested 7.42% in the stock. Edgar Lomax Co Va, a Virginia-based fund reported 822,876 shares.

The Allstate Corporation, together with its subsidiaries, engages in property-liability insurance and life insurance business in the United States and Canada. The company has market cap of $33.36 billion. The companyÂ’s Allstate Protection segment sells private passenger auto, homeowners, and other property-liability insurance products under the Allstate, Esurance, and Encompass brand names. It has a 11.35 P/E ratio. It also offers specialty auto products including motorcycle, trailer, motor home, and off-road vehicle insurance policies; other personal lines products including renter, condominium, landlord, boat, umbrella, and manufactured home insurance policies; commercial lines products for small business owners; roadside assistance products; service contracts; and other products sold in conjunction with auto lending and vehicle sales transactions.

The stock decreased 0.08% or $0.08 during the last trading session, reaching $94.92. About 1.85 million shares traded. The Allstate Corporation (ALL) has risen 15.17% since May 20, 2017 and is uptrending. It has outperformed by 3.62% the S&P500.

Ratings analysis reveals 50% of Allstate’s analysts are positive. Out of 2 Wall Street analysts rating Allstate, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. ALL was included in 3 notes of analysts from January 6, 2017. The rating was upgraded by Goldman Sachs on Tuesday, January 10 to “Buy”. The rating was downgraded by Credit Suisse to “Neutral” on Friday, January 6.

More important recent The Allstate Corporation (NYSE:ALL) news were published by: which released: “More Gains Coming For Small Caps After Hitting New Highs? (IWM)” on May 19, 2018, also published article titled: “Allstate Corporation 2018 Q1 – Results – Earnings Call Slides”, published: “Trupanion’s 10-K Risk Factor Section Raises Questions” on May 15, 2018. More interesting news about The Allstate Corporation (NYSE:ALL) was released by: and their article: “SEC Takes Closer Look At 5 NYSE Proposed Bitcoin ETFs” with publication date: April 24, 2018.

Investors sentiment increased to 1.22 in Q4 2017. Its up 0.23, from 0.99 in 2017Q3. It improved, as 73 investors sold AMGN shares while 458 reduced holdings. 122 funds opened positions while 527 raised stakes. 551.71 million shares or 0.60% less from 555.05 million shares in 2017Q3 were reported. Scott & Selber owns 15,547 shares or 1.45% of their US portfolio. Moreover, Smith Salley And has 0.62% invested in Amgen Inc. (NASDAQ:AMGN). Whittier Trust Of Nevada Incorporated accumulated 11,984 shares or 0.18% of the stock. 3,941 were reported by Diligent Ltd. 54,040 were reported by Provise Group Lc. Everence Cap Mngmt holds 0.66% or 17,379 shares. Schwartz Invest Counsel has 2.42% invested in Amgen Inc. (NASDAQ:AMGN) for 235,250 shares. Creative Planning reported 96,307 shares. 26,210 were reported by Cambridge. Birch Hill Investment Advsrs Limited, a Massachusetts-based fund reported 2,213 shares. Mercer Capital Advisers holds 0.63% or 4,983 shares in its portfolio. Moreover, Bkd Wealth Ltd has 0.07% invested in Amgen Inc. (NASDAQ:AMGN). Ameritas Invest Prtn invested in 0.31% or 40,018 shares. 1.87M are held by California Public Employees Retirement System. Calamos Wealth Limited Liability Company holds 0.44% of its portfolio in Amgen Inc. (NASDAQ:AMGN) for 19,280 shares.

Analysts await Amgen Inc. (NASDAQ:AMGN) to report earnings on July, 24. They expect $3.52 EPS, up 7.65% or $0.25 from last year’s $3.27 per share. AMGN’s profit will be $2.34 billion for 12.52 P/E if the $3.52 EPS becomes a reality. After $3.47 actual EPS reported by Amgen Inc. for the previous quarter, Wall Street now forecasts 1.44% EPS growth.

Since December 12, 2017, it had 0 insider purchases, and 6 sales for $1.64 million activity. Harper Sean E had sold 1,525 shares worth $289,369 on Friday, March 16.

More notable recent Amgen Inc. (NASDAQ:AMGN) news were published by: which released: “Amgen’s Novel Migraine Treatment Gets Key Approval” on May 18, 2018, also with their article: “Expanded label for Amgen’s Repatha approved in Europe” published on May 16, 2018, published: “Amgen’s Dim Sales Outlook Looms Over Buybacks” on April 26, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) were released by: and their article: “Better Buy: Amgen Inc. vs. Biogen Inc.” published on May 15, 2018 as well as‘s news article titled: “Why Spectrum Pharmaceuticals, Inc. Is Up Big Today” with publication date: May 17, 2018.

Among 25 analysts covering Amgen Inc. (NASDAQ:AMGN), 11 have Buy rating, 0 Sell and 14 Hold. Therefore 44% are positive. Amgen Inc. had 89 analyst reports since August 3, 2015 according to SRatingsIntel. The stock of Amgen Inc. (NASDAQ:AMGN) has “Buy” rating given on Friday, July 31 by Deutsche Bank. Bank of America upgraded Amgen Inc. (NASDAQ:AMGN) on Wednesday, February 1 to “Buy” rating. The company was initiated on Friday, December 4 by Wells Fargo. The firm earned “Hold” rating on Friday, August 26 by Gabelli. The stock of Amgen Inc. (NASDAQ:AMGN) has “Overweight” rating given on Thursday, October 26 by Morgan Stanley. The stock has “Market Perform” rating by BMO Capital Markets on Thursday, October 26. The stock of Amgen Inc. (NASDAQ:AMGN) earned “Buy” rating by Oppenheimer on Monday, June 19. As per Monday, February 12, the company rating was maintained by Mizuho. The firm has “Hold” rating by Jefferies given on Monday, June 12. On Wednesday, June 7 the stock rating was maintained by Bernstein with “Hold”.

Ci Investments Inc increased Newell Brands Inc (NYSE:NWL) stake by 242,306 shares to 1.98 million valued at $61.08 million in 2017Q4. It also upped Keycorp New (NYSE:KEY) stake by 614,800 shares and now owns 1.15 million shares. Wells Fargo & Co New (NYSE:WFC) was raised too.

The Allstate Corporation (NYSE:ALL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Recent Posts